Doctor's signs you have Covid not hay fever as UK hit by NB.1.8.1
Due do some overlap in symptoms it could be difficult to know if you have hay fever or coronavirus
Key symptoms can help tell apart a Covid infection from hay fever, despite some similarities in how they present. This year, millions of people in the UK have been tormented by the aggravating symptoms of hay fever, coinciding with "very high" pollen counts reported by the Met Office in certain regions.
Hay fever is an allergic response to airborne substances, predominantly pollen, leading to sneezing, nasal congestion, headaches, and sometimes even loss of smell. These symptoms are also common to COVID-19.
Doctor Luke Powles, associate clinical director at Bupa, explained: "Despite hay fever being more common during the spring and summer, some people are affected by pollen from March to September. This can make it harder to tell if sniffs and sneezes are being caused by an allergy or an infection such as coronavirus."
The relevance of this distinction has grown with the emergence of a new Covid strain known as NB. 1.8.1 (or Nimbus), which is making its way through the UK. According to recent figures from the UK Health Security Agency (UKHSA), there's been a near 10 per cent uptick in Covid-related hospital admissions, with 947 patients admitted in the week concluding on May 31.
However, differentiating hay fever from Covid is possible. The principal indicator to watch for is a high temperature, indicative of coronavirus but not associated with hay fever.
The NHS advises that this means "you feel hot to touch on your chest or back (you do not need to measure your temperature)". It may also lead to chills.
Dr Powles has clarified that it is "not likely" for you to experience a raised temperature as a result of hay fever. He said: "Although a blocked nose due to hay fever can affect your smell or taste, completely losing your ability to taste or smell is more likely to result from coronavirus."
Additionally, Covid tends to make people feel more unwell overall. "Hay fever symptoms aren't usually serious and, generally, you won't feel too ill," he added.
In contrast, Covid can be severe in certain instances and its symptoms may persist for weeks, months, or even years in the case of long Covid. The NHS notes: "The symptoms [of Covid] are very similar to symptoms of other illnesses, such as colds and flu.
"Most people feel better within a few weeks, but it can take longer to recover." Covid is also known to cause gastrointestinal issues, which are not associated with hay fever.
These symptoms can include nausea, vomiting, and diarrhoea. If you suspect you have contracted Covid, the advice is to self-isolate and avoid contact with others if you or your child exhibit symptoms and either:
Have a high temperature
Do not feel well enough to go to work, school, childcare, or carry out your normal activities.
According to the NHS, you can resume your "normal activities" once you feel better or no longer have a high temperature.
Typical hay fever symptoms consist of:
Sneezing and coughing
A runny or blocked nose
Itchy, red or watery eyes
Itchy throat, mouth, nose and ears
Loss of smell
Pain around your temples and forehead
Headache
Fatigue
Article continues below
Symptoms of Covid can encompass:
A high temperature or experiencing chills – this implies feeling hot to the touch on your chest or back (there's no need to take your temperature)
A new, persistent cough – this refers to coughing excessively for over an hour, or having three or more bouts of coughing within 24 hours
A loss or alteration in your sense of smell or taste
Breathlessness
Feeling fatigued or worn out
Bodily aches
A headache
A sore throat
A congested or runny nose
Loss of appetite
Diarrhoea
Feeling nauseous or vomiting
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Independent
12 minutes ago
- The Independent
Weight loss pill shows promise in new trial
A new weight loss medication, which can be offered by injection or tablet, can help patients lose a significant amount weight, studies suggest. An early study have found that people who received higher doses of amycretin as a weekly jab lost 24.3% of their body weight after 36 weeks of treatment. And initial trials assessing a tablet form of the drug also showed promising results, with patients taking daily tablets losing an average of 13.1% of their body weight after 12 weeks. Weight loss jabs have been hailed as transformative by NHS leaders. But injections come with additional work for over-stretched health services so tablet forms of medication may offer a new hope for the millions of people looking to lose weight. It has been estimated that around 1.5 million Britons are having weight loss jabs, which have been either prescribed through specialist weight loss services or private prescriptions. GPs will be able to dish out that jabs from next week. Amycretin, made by Novo Nordisk, helps to control blood sugar and appetite by targeting two specific receptors in the body – GLP-1 and the amylin receptor. An early trial in 125 adults testing weekly injections of amycretin, which has been published in The Lancet, found that those taking the highest dosage (60mg) lost 24.3% after 36 weeks of treatment. It also showed signs in improving blood sugar levels. Side effects included nausea and vomiting and were mostly mild to moderate and resolved by the end of treatment. 'These phase 1b/2a data support the potential of once-weekly subcutaneous amycretin as a therapeutic for people living with overweight or obesity,' the authors wrote. 'Amycretin appeared safe and tolerable, and there were significant reductions in body weight after 36 weeks of treatment.' The second early trial, published in the same journal, assessed amycretin in tablet form in 144 people over 12 weeks. There were mild to moderate side effects including loss of appetite, nausea and vomiting. Researchers found that people taking the highest dose of 100mg per day, lost 13.1% of their body weight over four months. The authors wrote: 'Amycretin effectively lowered body weight and improved metabolic and glycaemic parameters in people with overweight or obesity. 'Longer studies with more participants are warranted for evaluation of the safety and efficacy of amycretin in individuals living with obesity and type 2 diabetes, and to optimise the dosing regimen.' The studies were also presented at the American Diabetes Association's Scientific Sessions in Chicago, in the US. It comes as a separate study, which was published at the same meeting, examined the effects of weight loss jab Wegovy at higher doses. Researchers found that giving patients 7.2mg of Wegovy, also known as semaglutide, once a week led to an average weight loss of 20.7%, with a third of participants losing 25% or more of their body weight after 72 weeks.
South Wales Guardian
27 minutes ago
- South Wales Guardian
Weight loss pill shows promise in new trial
An early study have found that people who received higher doses of amycretin as a weekly jab lost 24.3% of their body weight after 36 weeks of treatment. And initial trials assessing a tablet form of the drug also showed promising results, with patients taking daily tablets losing an average of 13.1% of their body weight after 12 weeks. Weight loss jabs have been hailed as transformative by NHS leaders. But injections come with additional work for over-stretched health services so tablet forms of medication may offer a new hope for the millions of people looking to lose weight. It has been estimated that around 1.5 million Britons are having weight loss jabs, which have been either prescribed through specialist weight loss services or private prescriptions. GPs will be able to dish out that jabs from next week. Amycretin, made by Novo Nordisk, helps to control blood sugar and appetite by targeting two specific receptors in the body – GLP-1 and the amylin receptor. An early trial in 125 adults testing weekly injections of amycretin, which has been published in The Lancet, found that those taking the highest dosage (60mg) lost 24.3% after 36 weeks of treatment. It also showed signs in improving blood sugar levels. Side effects included nausea and vomiting and were mostly mild to moderate and resolved by the end of treatment. 'These phase 1b/2a data support the potential of once-weekly subcutaneous amycretin as a therapeutic for people living with overweight or obesity,' the authors wrote. 'Amycretin appeared safe and tolerable, and there were significant reductions in body weight after 36 weeks of treatment.' The second early trial, published in the same journal, assessed amycretin in tablet form in 144 people over 12 weeks. There were mild to moderate side effects including loss of appetite, nausea and vomiting. Researchers found that people taking the highest dose of 100mg per day, lost 13.1% of their body weight over four months. The authors wrote: 'Amycretin effectively lowered body weight and improved metabolic and glycaemic parameters in people with overweight or obesity. 'Longer studies with more participants are warranted for evaluation of the safety and efficacy of amycretin in individuals living with obesity and type 2 diabetes, and to optimise the dosing regimen.' The studies were also presented at the American Diabetes Association's Scientific Sessions in Chicago, in the US. It comes as a separate study, which was published at the same meeting, examined the effects of weight loss jab Wegovy at higher doses. Researchers found that giving patients 7.2mg of Wegovy, also known as semaglutide, once a week led to an average weight loss of 20.7%, with a third of participants losing 25% or more of their body weight after 72 weeks.
Leader Live
42 minutes ago
- Leader Live
Weight loss pill shows promise in new trial
An early study have found that people who received higher doses of amycretin as a weekly jab lost 24.3% of their body weight after 36 weeks of treatment. And initial trials assessing a tablet form of the drug also showed promising results, with patients taking daily tablets losing an average of 13.1% of their body weight after 12 weeks. Weight loss jabs have been hailed as transformative by NHS leaders. But injections come with additional work for over-stretched health services so tablet forms of medication may offer a new hope for the millions of people looking to lose weight. It has been estimated that around 1.5 million Britons are having weight loss jabs, which have been either prescribed through specialist weight loss services or private prescriptions. GPs will be able to dish out that jabs from next week. Amycretin, made by Novo Nordisk, helps to control blood sugar and appetite by targeting two specific receptors in the body – GLP-1 and the amylin receptor. An early trial in 125 adults testing weekly injections of amycretin, which has been published in The Lancet, found that those taking the highest dosage (60mg) lost 24.3% after 36 weeks of treatment. It also showed signs in improving blood sugar levels. Side effects included nausea and vomiting and were mostly mild to moderate and resolved by the end of treatment. 'These phase 1b/2a data support the potential of once-weekly subcutaneous amycretin as a therapeutic for people living with overweight or obesity,' the authors wrote. 'Amycretin appeared safe and tolerable, and there were significant reductions in body weight after 36 weeks of treatment.' The second early trial, published in the same journal, assessed amycretin in tablet form in 144 people over 12 weeks. There were mild to moderate side effects including loss of appetite, nausea and vomiting. Researchers found that people taking the highest dose of 100mg per day, lost 13.1% of their body weight over four months. The authors wrote: 'Amycretin effectively lowered body weight and improved metabolic and glycaemic parameters in people with overweight or obesity. 'Longer studies with more participants are warranted for evaluation of the safety and efficacy of amycretin in individuals living with obesity and type 2 diabetes, and to optimise the dosing regimen.' The studies were also presented at the American Diabetes Association's Scientific Sessions in Chicago, in the US. It comes as a separate study, which was published at the same meeting, examined the effects of weight loss jab Wegovy at higher doses. Researchers found that giving patients 7.2mg of Wegovy, also known as semaglutide, once a week led to an average weight loss of 20.7%, with a third of participants losing 25% or more of their body weight after 72 weeks.
